Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 360


Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.

Martin L, Kaci N, Estibals V, Goudin N, Garfa-Traore M, Benoist-Lasselin C, Dambroise E, Legeai-Mallet L.

Hum Mol Genet. 2018 Jan 1;27(1):1-13. doi: 10.1093/hmg/ddx374.


Chondrocyte FGFR3 Regulates Bone Mass by Inhibiting Osteogenesis.

Wen X, Li X, Tang Y, Tang J, Zhou S, Xie Y, Guo J, Yang J, Du X, Su N, Chen L.

J Biol Chem. 2016 Nov 25;291(48):24912-24921. Epub 2016 Oct 11.


Fibroblast Growth Factor Receptor 3 Deficiency Does Not Impair the Osteoanabolic Action of Parathyroid Hormone on Mice.

Xie Y, Yi L, Weng T, Huang J, Luo F, Jiang W, Xian CJ, Du X, Chen L.

Int J Biol Sci. 2016 Jul 17;12(8):990-9. doi: 10.7150/ijbs.14077. eCollection 2016.


Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Komla-Ebri D, Dambroise E, Kramer I, Benoist-Lasselin C, Kaci N, Le Gall C, Martin L, Busca P, Barbault F, Graus-Porta D, Munnich A, Kneissel M, Di Rocco F, Biosse-Duplan M, Legeai-Mallet L.

J Clin Invest. 2016 May 2;126(5):1871-84. doi: 10.1172/JCI83926. Epub 2016 Apr 11.


Conditional Deletion of Fgfr3 in Chondrocytes leads to Osteoarthritis-like Defects in Temporomandibular Joint of Adult Mice.

Zhou S, Xie Y, Li W, Huang J, Wang Z, Tang J, Xu W, Sun X, Tan Q, Huang S, Luo F, Xu M, Wang J, Wu T, Chen L, Chen H, Su N, Du X, Shen Y, Chen L.

Sci Rep. 2016 Apr 4;6:24039. doi: 10.1038/srep24039.


Deletion of FGFR3 in Osteoclast Lineage Cells Results in Increased Bone Mass in Mice by Inhibiting Osteoclastic Bone Resorption.

Su N, Li X, Tang Y, Yang J, Wen X, Guo J, Tang J, Du X, Chen L.

J Bone Miner Res. 2016 Sep;31(9):1676-87. doi: 10.1002/jbmr.2839. Epub 2016 Apr 13.


FGF Signaling Is Necessary for Neurogenesis in Young Mice and Sufficient to Reverse Its Decline in Old Mice.

Kang W, Hébert JM.

J Neurosci. 2015 Jul 15;35(28):10217-23. doi: 10.1523/JNEUROSCI.1469-15.2015.


Micro CT Analysis of Spine Architecture in a Mouse Model of Scoliosis.

Gao C, Chen BP, Sullivan MB, Hui J, Ouellet JA, Henderson JE, Saran N.

Front Endocrinol (Lausanne). 2015 Mar 19;6:38. doi: 10.3389/fendo.2015.00038. eCollection 2015.


Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.

Garcia S, Dirat B, Tognacci T, Rochet N, Mouska X, Bonnafous S, Patouraux S, Tran A, Gual P, Le Marchand-Brustel Y, Gennero I, Gouze E.

Sci Transl Med. 2013 Sep 18;5(203):203ra124. doi: 10.1126/scitranslmed.3006247.


Fibroblast growth factor receptor 3 regulates microtubule formation and cell surface mechanical properties in the developing organ of Corti.

Szarama KB, Stepanyan R, Petralia RS, Gavara N, Frolenkov GI, Kelley MW, Chadwick RS.

Bioarchitecture. 2012 Nov-Dec;2(6):214-9. doi: 10.4161/bioa.22332.


Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.

Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L.

Am J Hum Genet. 2012 Dec 7;91(6):1108-14. doi: 10.1016/j.ajhg.2012.10.014. Epub 2012 Nov 29.


A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, Du X, Xian CJ, Liu P, Huang H, Shen Y, Deng CX, Chen D, Chen L.

Hum Mol Genet. 2012 Dec 15;21(26):5443-55. doi: 10.1093/hmg/dds390. Epub 2012 Sep 26.


Phenotype profile of a genetic mouse model for Muenke syndrome.

Nah HD, Koyama E, Agochukwu NB, Bartlett SP, Muenke M.

Childs Nerv Syst. 2012 Sep;28(9):1483-93. doi: 10.1007/s00381-012-1778-9. Epub 2012 Aug 8.


Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.

Xie Y, Su N, Jin M, Qi H, Yang J, Li C, Du X, Luo F, Chen B, Shen Y, Huang H, Xian CJ, Deng C, Chen L.

Hum Mol Genet. 2012 Sep 15;21(18):3941-55. doi: 10.1093/hmg/dds181. Epub 2012 May 24.


Muenke syndrome mutation, FgfR3P²⁴⁴R, causes TMJ defects.

Yasuda T, Nah HD, Laurita J, Kinumatsu T, Shibukawa Y, Shibutani T, Minugh-Purvis N, Pacifici M, Koyama E.

J Dent Res. 2012 Jul;91(7):683-9. doi: 10.1177/0022034512449170. Epub 2012 May 23.


An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.

Mugniery E, Dacquin R, Marty C, Benoist-Lasselin C, de Vernejoul MC, Jurdic P, Munnich A, Geoffroy V, Legeai-Mallet L.

Hum Mol Genet. 2012 Jun 1;21(11):2503-13. doi: 10.1093/hmg/dds065. Epub 2012 Feb 24.


A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.

Jonquoy A, Mugniery E, Benoist-Lasselin C, Kaci N, Le Corre L, Barbault F, Girard AL, Le Merrer Y, Busca P, Schibler L, Munnich A, Legeai-Mallet L.

Hum Mol Genet. 2012 Feb 15;21(4):841-51. doi: 10.1093/hmg/ddr514. Epub 2011 Nov 9.


The Muenke syndrome mutation (FgfR3P244R) causes cranial base shortening associated with growth plate dysfunction and premature perichondrial ossification in murine basicranial synchondroses.

Laurita J, Koyama E, Chin B, Taylor JA, Lakin GE, Hankenson KD, Bartlett SP, Nah HD.

Dev Dyn. 2011 Nov;240(11):2584-96. doi: 10.1002/dvdy.22752.


Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome.

Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM, Wilkie AO.

Dev Dyn. 2009 Feb;238(2):331-42. doi: 10.1002/dvdy.21790.


Gain-of-function mutation of FGFR3 results in impaired fracture healing due to inhibition of chondrocyte differentiation.

Su N, Yang J, Xie Y, Du X, Lu X, Yin Z, Yin L, Qi H, Zhao L, Feng J, Chen L.

Biochem Biophys Res Commun. 2008 Nov 21;376(3):454-9. doi: 10.1016/j.bbrc.2008.08.165. Epub 2008 Sep 24.


Supplemental Content

Support Center